Microfluidic Assessment of Clinical Outcomes in Preterm Newborns
Key facts
- Who runs it
- University of Florida
- Where
- Gainesville, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- People taking part
- 293 people enrolled
- Started
- 14 Nov 2017
- Expected to end
- 31 Dec 2026
- Type of study
- Observational, 3 groups
- Treatments tested
- Blood Collection Preterm
- Blood Collection Term
- Adult Blood collection
- Record updated
- 13 February 2026
Who can take part
- Age
- 23 weeks to 42 weeks
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- For preterm neonates <32 weeks gestation at birth with no known or suspected congenital anomalies
- For term neonates >36 weeks gestation at birth with no known or suspected congenital anomalies
Who cannot take part
- Congenital defects, suspected genetic disorders, 32-36 weeks completed gestation, or lack of consent; Healthy Adult:
- Exclusion Criteria Taking any immune modifying medications or have an active immune modifying disease process
- Inclusion criteria Between the ages of 18 and 65 years of age
Where in United States
- UF HealthGainesville, United States
About the trial
What the trial wants to find out
Sepsis has its greatest impact in the prematurely born (preterm) population. Neonatal sepsis (sepsis within the first month of life) causes over one million deaths worldwide annually, and is one of the most common, difficult and costly problems to diagnose, treat and prevent. The preterm infant can suffer rates of sepsis up to 1000-fold higher than the full-term infant, and bears the brunt of the associated mortality and lifelong sepsis-survivor morbidity.
Read full original descriptionShow less
The project is enabled by several novel, validated, microfluidic technologies that are robust and easy to use with little training. These technologies provide comprehensive measures of the functionality of blood PMN population; a critical cellular component of innate immunity. The study team will also extract high-quality nucleic acids from microfluidic-sorted PMNs for transcriptomic analyses. Collectively, these techniques require a total of 250 microliters (µL) of blood, which makes them particularly useful for preterm infants where sample volume is limited, and facilitates serial assessments with unprecedented temporal resolution of key functions of PMNs.
These studies, integrated with bioinformatics approaches, will generate new tools for diagnosing sepsis in the newborn and predicting clinical outcomes. Such approaches have the capability to dramatically change the clinical management of the preterm infant, and potentially improve long-term outcomes while reducing hospital costs.
The 3 groups in the trial
- Preterm Neonates
Blood collection Preterm. From blood, the speed, directionality, and persistence of PMN chemotaxis using microfluidic devices and transcriptomic analysis will be measured.
Treatment: Blood Collection Preterm
- Term Neonates
Blood collection Term. From blood, the speed, directionality, and persistence of PMN chemotaxis using microfluidic devices and transcriptomic analysis will be measured.
Treatment: Blood Collection Term
- Healthy Adult
One-time whole blood draw of 1ml collection
Treatment: Adult Blood collection
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 13 February 2026